瑞替普酶溶栓治疗急性心肌梗死25例临床分析

The clinical analysis of reteplase thrombolytic therapy in 25 cases with acute myocardial infarction

目的：观察瑞替普酶治疗急性ST段抬高型心肌梗死的疗效及安全性.方法：选取符合溶栓条件的急性心肌梗死患者25 例,采用瑞替普酶18 mg 缓慢推注2 min 以上,半小时后重复给予-次的方法.观察冠脉血管再通率、不良反应及病死率.结果：溶栓总再通率92%,其中发病2 h内溶栓再通率100%,2 ～ 6 h内再通率88.9%.结论：瑞替普酶是治疗急性心肌梗死安全可靠、方便快捷的溶栓药物,在不具备介入治疗条件的基层医院值得临床推广.

Objective： To observe the efficacy and safety of reteplase on the treatment of acute ST elevation myocardialinfarction. Methods： A total of 25 cases of patients with acute myocardial infarction who were eligible for thrombolysis were treatedwith reteplase 18 mg by slow intravenous injection （about 2 minutes or more）, and reteplase was given again after half an hour. Thecoronary recanalization rate, adverse reactions and mortality were observed. Results： The total thrombolytic recanalization rate was92%, it was 100% in the patients used reteplase within 2 h, and 88.9% within 2 – 6 h. Conclusion： Reteplase is a safe, reliable,convenient and efficient drug on the treatment of acute myocardial infarction, which can be used widely in the primary hospital withno condition for interventional therapy.